A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 09 Jul 2019 Status changed from completed to discontinued.
- 27 Jun 2019 Status changed from active, no longer recruiting to completed.
- 24 Apr 2018 Status changed from completed to active, no longer recruiting.